Methods and compositions for treating glucocorticoid excess
AssigneeSparrow Pharmaceuticals, Inc.
InventorDavid A. Katz
Life of this patent
Estimating the term…
Abstract
The disclosure provides a method of treatment for glucocorticoid excess in a patient in need thereof, comprising administering to the patient a pseudo-irreversible HSD-1 inhibitor.
Claims29
A method for treating one or more symptoms of glucocorticoid excess in a human patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:
- wherein the therapeutically effective amount of the compound, or the pharmaceutically acceptable salt thereof, is about 1 mg to about 40 mg daily,
- wherein the one or more symptoms of glucocorticoid excess are selected from the group consisting of cardiovascular, metabolic, immunologic, osteal, muscular, dermatological, ocular, psychiatric, cognitive, circadian, and homeostatic symptoms,
- wherein the compound does not show tachyphylaxis for HSD-1 inhibition in human adipose tissue, and
- wherein the treatment lowers an intracellular cortisol level in the patient.
A method for treating one or more osteal symptoms of glucocorticoid excess in a human patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:
- wherein the therapeutically effective amount of the compound, or the pharmaceutically acceptable salt thereof, is about 1 mg to about 40 mg daily.
A method for treating one or more cardiovascular symptoms of glucocorticoid excess in a human patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:
- wherein the therapeutically effective amount of the compound, or the pharmaceutically acceptable salt thereof, is about 1 mg to about 40 mg daily.
A method for treating one or more metabolic symptoms of glucocorticoid excess in a human patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:
- wherein the therapeutically effective amount of the compound, or the pharmaceutically acceptable salt thereof, is about 1 mg to about 40 mg daily.
Dependencies are inferred from the claim text.